Rituximab has proven to be effective in other monoclonal gammopathies by decreasing the antibodies causing the diseases, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), anti-MAG, or multifocal motor neuropathy (MMN) [16]. The gene discussed is MAG; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.